Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US-2016376224-A1 · Dec 29, 2016 · US
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
US11660332B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11660332-B2 |
| Application number | US-201816608392-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2018 |
| Priority date | Apr 27, 2017 |
| Publication date | May 30, 2023 |
| Grant date | May 30, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A lineage vaccine comprising a combination of isolated nucleoside-modified RNA molecules, wherein the combination of isolated nucleoside-modified RNA molecules encodes a combination of sequential lineage antigens for inducing an immune response against Hepatitis C virus (HCV) in a subject, wherein the combination of isolated nucleoside-modified RNA molecules comprises at least one isolated nucleoside-modified RNA molecule encoding each of the HCV antigens as set forth in SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ. ID NO:34, SEQ ID NO:35 and SEQ ID NO:36. 2. The lineage vaccine of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises a nucleoside selected from the group consisting of pseudouridine and 1-methyl-pseudouridine. 3. The lineage vaccine of claim 1 , wherein the at least one isolated nucleoside-modified RNA is a purified nucleoside-modified RNA. 4. The lineage vaccine of claim 1 , wherein the combination of nucleoside-modified RNA molecules comprises RNA sequences encoded by DNA sequences comprising: SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27. 5. The lineage vaccine of claim 1 , comprising a combination of lipid nanoparticles (LNPs) encapsulating the isolated RNA molecules. 6. The lineage vaccine of claim 1 , wherein the at least one nucleoside-modified RNA further encodes at least one adjuvant. 7. The lineage vaccine of claim 5 , wherein each nucleoside-modified RNA is encapsulated within a different LNP. 8. The lineage vaccine of claim 1 , wherein the composition is a vaccine.
Assignees
Inventors
Classifications
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
DNA (RNA) vaccination · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title
Hepatitis virus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11660332B2 cover?
- The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine c…
- Who is the assignee on this patent?
- Univ Pennsylvania, Univ Johns Hopkins, Univ Vanderbilt, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).